A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerTherapeutic options for intrahepatic cholangiocarcinomaSystemic Therapy of Cholangiocarcinoma.SU11274 suppresses proliferation and motility of pancreatic cancer cells.Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.Intrahepatic cholangiocarcinoma: current management and emerging therapies.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Emerging molecular therapeutic targets for cholangiocarcinoma.Tivantinib for the treatment of hepatocellular carcinoma.Cholangiocarcinoma - evolving concepts and therapeutic strategies.A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Targeting cholangiocarcinoma.New molecular and immunotherapeutic approaches in biliary cancer.
P2860
Q26751224-E08356EF-274F-4F12-B3F0-7D1105C536D6Q28067777-0179F648-95DC-4B17-8694-4A9D6D29BE79Q33621529-99EB477C-329F-4533-9DD2-3996043181CEQ34551877-938F4E87-17B3-4C39-A1FB-95ADDD51B738Q35944581-A9E183C5-8F4E-41E9-B822-421515F65A42Q38782345-32D54775-657F-4FB9-8BF1-DF009A474CD5Q38824065-8F1D1D95-35B7-48D1-B3E7-1BC31802E7CFQ39186928-87AD6804-6B19-4BE0-90A5-17BC252B9158Q39204274-E9C81D69-B9DF-4A80-9A7E-BA9F4FF67F17Q39227356-BA82B831-9645-4B97-9640-FF7148387D1EQ39246053-30EB1A35-0059-4083-A494-354E910174B1Q46087686-63E53C1B-D1B5-4813-A6F4-5D7CD9EB9F3BQ49881127-19FC75FC-5DB9-4192-8C55-D8FC556AD6AEQ50231382-D949FFCF-2FB5-4473-ABDF-5232E9BE65E3Q50985091-F0932889-58A6-4E45-9D15-F7A80331C3BFQ52757760-DD77040A-61F0-43FC-B417-0FC31F082396Q54476966-83B7A493-4C72-4E78-8612-48DACCC8723B
P2860
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I dose escalation stud ...... in patients with solid tumors.
@ast
A phase I dose escalation stud ...... in patients with solid tumors.
@en
type
label
A phase I dose escalation stud ...... in patients with solid tumors.
@ast
A phase I dose escalation stud ...... in patients with solid tumors.
@en
prefLabel
A phase I dose escalation stud ...... in patients with solid tumors.
@ast
A phase I dose escalation stud ...... in patients with solid tumors.
@en
P2093
P2860
P356
P1433
P1476
A phase I dose escalation stud ...... in patients with solid tumors.
@en
P2093
C D Kurkjian
G Abbadessa
J R Infante
P2860
P304
P356
10.1093/ANNONC/MDU157
P577
2014-04-15T00:00:00Z